|
Adult measles vaccination recommendations have been in the spotlight during the recent nationwide measles outbreak. The CDC published an infographic to assist with clinical decision making: Measles vaccine recommendations for non-pregnant adults aged 19 or older, by birth year in the United States (PDF).
 You can find translated resources on Measles (Rubeola) Basics, including a short, graphic measles, mumps, and rubella (MMR) vaccine video in English, Hmong, Somali, and Spanish. The Measles Information for Health Professionals page includes information on vaccinating domestic travelers and provides quick and easy access to critical clinical content.
On June 25, the Secretary of Health and Human Services (HHS) adopted the following meningococcal ABCWY and adult respiratory syncytial virus (RSV) vaccine recommendations made during the April meeting.
-
Meningococcal: GSK's MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit for healthy persons aged 16–23 years when shared clinical decision-making favors administration of MenB vaccine and persons aged 10 years of age and older who are at increased risk for meningococcal disease. There are now two pentavalent meningococcal products available, Penmenvy (GSK) and Penbraya (Pfizer). These MenB products are not interchangeable. A series started with one brand must be completed with the same brand.
-
RSV: Adults aged 50–59 years of age with chronic medical conditions and other risk factors for severe RSV disease should receive a single dose of the vaccine. This is in addition to current recommendations for high-risk adults 60-74 and all adults 75 years of age and older. This recommendation applies to all three RSV adult products, mResvia, Arexvy, and Abrysvo. Adult RSV vaccination using any licensed brand is recommended as a single lifetime dose.
These are now official CDC recommendations and have been added to the addenda of both the adult and child and adolescent CDC: Immunization Schedules and CDC: ACIP Recommendations. For additional information on clinical considerations, refer to: CDC: Meningococcal Vaccine Recommendations and CDC: RSV Vaccine Guidance for Adults.
The meningococcal ABCWY and RSV adult Vaccine Protocols templates have been updated to reflect the new recommendations.
On July 22, the HHS Secretary approved the ACIP recommendation from the June meeting to allow only single-dose formulations of annual influenza vaccines that are free of thimerosal as a preservative for children, pregnant women, and all adults. The remaining ACIP recommendations which included approval of clesrovimab/Enflonsia (Merck’s RSV monoclonal antibody product) and seasonal influenza vaccine for everyone 6 months of age and older are still under review and are not yet considered official.
The next ACIP meeting will be held in August or September with a specific date and time to be determined. All meetings are live and open for public viewing. For more information visit CDC: Advisory Committee on Immunization Practices (ACIP).
|
